Generic Name: sipuleucel-T
Drug Class: Immunotherapy Medications
Approval Status: Approved
Generic Version Available: No
Provenge is a personalized cancer vaccine approved for metastatic prostate cancer that does not respond to hormone therapy (known as castration-resistant).
The Provenge vaccine works by removing a sample of dendritic cells (a type of immune cell that presents antigens to T cells), exposing them to a common prostate tumor antigen in a lab and returning them to the patient. The modified cells are then better able to recognize and attack prostate cancer.
Clinical trials showed that Provenge slows progression of prostate cancer and prolongs survival by about five months.
Provenge involves three intravenous infusions of modified T cells given about two weeks apart. The turnaround time from cell collection to reinfusion of the modified cells is usually around three days.
Common side effects include fatigue, chills, fever, nausea, back pain, joint pain and headache.
For More Info: https://www.provenge.com/
Patient Assistance Program Info: https://www.pparx.org/prescription_assistance_programs/provenge_patient_assistance_program
Last Reviewed: September 18, 2018